“A sweetheart deal” “deplorable” “immoral and unacceptable” “Massive victory for big pharma” . . . We’re reading about TPP’s pharma rules, and an update on a 5000-percent price hike
(Spoiler alert: The price of a life-saving treatment for toxoplasmosis remains unchanged, a month after company CEO Martin Shkreli said it would drop . . . ) But first: The world got glimpse of what the Trans Pacific Partnership offers pharmaceutical companies last week with the WikiLeaks release of the treaty’s Intellectual Property Rights chapter, a […]